Hepatitis B Clinical Trial
Official title:
Lay Health Worker Model to Reduce Liver Cancer Disparities in Asian Americans
The study was conducted between April 2013 and October 2014. In the parent study, 600
foreign-born Asian American adults 18 years of age and older were drawn from the community
in the Baltimore Washington Metropolitan Area. Using a non-probability sampling method,
foreign-born Asian American adults, 18 years of age and older, were recruited from the
community.
After providing informed consent, all the participants were asked to complete a
self-administered questionnaire in English, Chinese, Korean, or Vietnamese with the
assistance of a bilingual interviewer when necessary. Then, all of the participants were
instructed and given 5 to 10 to minutes to read culturally integrated and linguistically
appropriate educational material (e.g., Photo novel) developed and validated for efficacy
from a prior study.
All participants received hepatitis B testing: HBsAg (hepatitis B surface antigen), HBsAb
(hepatitis B surface antibody) and, HBcAb (hepatitis B core antibody). A total of 600
completed the survey and screening. A week later, they received the results of the screening
test. Based on the screening results, all participants were categorized into three groups:
(1) infected (HbsAg+), (2) unprotected (HbsAg-/HbsAb-), or (3) protected (HbsAg-/HbsAb+). We
sent the results by mail to participants who were unprotected and protected. Among those 600
screened participants, 33(5.5%) had chronic hepatitis B virus (HBV) infection and 335
(55.8%) had evidence of resolved HBV infection (protected). A total of 232 (38.7%) were
susceptible to HBV infection (unprotected).
LHW (lay health worker) Intervention for those unprotected: Those unprotected (n=232) were
randomly assigned to either the intervention (n=124) or the control (n=108) groups by
computer-automated random assignment. Randomization was used to assure equivalence between
groups on key factors that may potentially influence the outcome of HBV vaccinations:
gender, age, education, length of stay in the U.S.
LHWs conducted phone interventions by reminding participants of a series of vaccinations at
months 1, 2, and 5 among those assigned to the intervention group. Those in the control
group received a list of resources along with their results by mail that offered free
vaccinations, such as local health departments. Seven months after mailing the results,
those unprotected were followed up by phone to ask about their status of the series of
vaccinations and about promoters or barriers to vaccinations.
Specific Aim 1. Develop a training protocol and certification program for lay health workers
(LHWs)
People of Asian backgrounds are likely to exhibit cultural relativism leaning toward
collectivism compared to individualism. The personal interactions within their
self-identified cultural communities may closely relate to development of their perceived
beliefs and subjective norms, which influence to act upon identified health behaviors
(Ajzen, Albarracin & Hornik 2007). The investigators will develop a lay health worker (LHW)
model that highlights the effects of culturally competent human and educational interactions
on facilitating the Chinese-, Korean- and Vietnamese-American (CKV-A) community's active
behaviors in hepatitis B screening, vaccination, and treatments. To develop an efficacious
and effective LHW intervention that will contribute for creating a critical mass toward
sustainable Chinese, Korean and Vietnamese (CKV) changes, our strategic approaches include
as follows:
1. Review the liver cancer education program guidebook in English, (developed by previous
project R25).
2. Refine/revise the approaches through work group reviews: Through a series of bi-monthly
meetings with participants from community advisory board (CAB), CKV-A communities,
health practitioners and outreach workers, and experts in hepatitis B virus (HBV) and
liver cancer education (Juon and Lee), and education and evaluation (Park), the
investigators will confirm/specify the approaches of the available materials and
develop additional assessment approaches and forms in English.
3. Test the validities of subgroup language versions with pilot CKV groups: Through
assessments with each group (n=10) of CKV-As, the investigators will produce the
refined validated LHW protocol (after translation and back-translation). It will
include common and unique approaches across/within subgroup(s) to be congruent with
cultural values.
4. Test the pilot LHW implementation
5. Establish the LHW model to certify satisfactory practicum experience in Patient
Navigation training module: Through ongoing assessments with the study participants and
participating health care systems, the investigators will monitor the LHW experiential
learning module to provide patient navigation function. The approach will identify
barriers to hinder access to timely screening, follow-up, and treatment upon diagnosis.
Recruitment: Earp et al. (1997) suggest effective LHWs would have some or all of the
following characteristics and skills: (1) the ability to comfortably and effectively access
the health care system; (2) the ability to balance the demands of lay helping with other
life responsibilities; (3) an interest in AA's health and social issues; (4) maintain close,
supportive, and reciprocal connections with others; and (5) leadership skills. LHW models
depend on genuine natural helpers to function. To increase recruitment potential for CKVs
having desired characteristics: First, the investigators will reach a broad pool of adult
volunteers, regardless of gender, income level, or health care experience, who have these
characteristics and also have the ability to speak, read and write Chinese, Korean, or
Vietnamese languages at or above 2nd grade level. Second, adopting a referral recruitment
strategy in social market theory (Lefebvre et al. 1988) as it may be more effective for
people who may be more responsive to their sense of collective cultural group's
interactions, the investigators will recruit the first 10 LHW candidates per each ethnic
group referred by word of mouth, faith-based organization leaders, community advisory
groups, and health and social service agencies. Finally, the investigators will expand our
recruitment continuously in the community. In Year 1, the investigators plan to train a
total of 60 certified LHWs (20 from each ethnic group). The investigators estimate retention
of 40 (67%) certified LHWs at the end of the Year 1, based upon literature reviews (Anderson
2000; Caulfield et al. 1998; Han et al. 2009). To replace drop-out LHWs in subsequent years,
the investigators plan to recruit and train a total of 30 additional LHWs (10 for each
ethnic group) from Years 2 to 3.
Process Evaluation: Using evaluation model of Reach, Effectiveness, Adoption, Implementation
and Maintenance (RE-AIM) (Glasgow et al. 2001), a framework that emphasized on Reach,
Effectiveness, Adoption, Implementation and Maintenance, the investigators will examine the
extent to which the LHW program is carried out through processes as intended. At individual
level, the investigators will focus on Reach (R) of the LHW certification program and
hepatitis B free events and on the Efficacy/Effectiveness (E) of the LHW certification
program. For the group level of aggregated individuals, the investigators will assess on
Adoption (A), Implementation (I), and Maintenance (M). The investigators will assess general
administrative processes of LHW program during the study period in the selected perspectives
of fidelity (e.g. logistic reviews, completion rates), dose (e.g. satisfaction survey), and
method on translated forms and tools (Saunders, Evans, & Joshi 2005).
Specific Aim 2. To assess the prevalence of HBV infection by providing screening test
A total of 600 Asian American adults (200 Chinese, Koreans, and Vietnamese each), 18 years
of age and older will be drawn from the community.
Recruitment strategy. The investigators have two major channels to recruit participants with
the help of certified LHWs including hepatitis B initiative of Washington DC (HBI-DC)
screening events and Asian American Health Center (AAHC). First, in the past 10 years, the
HBI-DC has screened over 3000 individuals in the Baltimore-Washington Metropolitan Area and
approximately 8 to 11% are positive for the surface antigen of the hepatitis B virus
(HBsAg). Thus, many individuals are availing themselves of the free testing services. LHWs
will announce upcoming screening events in their community by advertising in Korean churches
or Chinese language schools or by word-of-mouth. Our research team and LHWs will attend
these events to recruit potential participants. Based on previous experiences, each
screening event attracted about 100 to 150 Asian Americans. Second, the investigators will
go to AAHC volunteer clinics to recruit participants every Saturday. About 10 to 12 Chinese
or Korean patients visit the clinic. Patients usually come with family members. So, the
investigators estimate to recruit about 15 to 20 participants at the clinics every Saturday.
Finally, the investigators will identify potential participants by advertising in ethnic
media and ethnic groceries.
Sample size estimate: Based on our previous studies (Juon et al. 2008; Hsu et al. 2007), the
investigators estimate that about 10% of all the participants will test hepatitis B virus
(HBV) positive, 40 to 50% will be HBV negative but protected, and about 50% will be
unprotected. In the preliminary analysis of R25, there were significant mean differences of
knowledge of HBV transmission (score ranged 0-10) in intervention (7.21±1.83SD) and control
group (5.54±2.07SD) in post-test. The investigators estimated our sample size to be 50 in
each intervention and control group among those unprotected. Assuming a conservative rate of
attrition about 20%, the investigators calculated the study power based on sample size at
follow-up. The sample size of 50 at pre-test is to detect mean difference in knowledge
outcome at 96% power (1-β) and type I error of 0.05.Thus, our proposed sample size (n=50)
for each group among those unprotected has sufficient power. Our total sample size is 600
(50/group x 2 groups x 2 (infected and protected-50% of study population) x 3 ethnic
groups).
Specific Aim 3. To implement LHW intervention among those unprotected Procedures
1. Pre-test/Education program: After obtaining the informed consent for pre-test,
screening test, and blood banking, all the participants will be asked to complete a
self-administered questionnaire in English, Chinese, Korean, or Vietnamese, with the
assistance of a bilingual interviewer when necessary. Then, LHW will provide a liver
cancer education session to all participants in a small group setting.
2. HBV screening test/initial biospecimen banking: All participants will receive hepatitis
B testing. For blood sampling procedure, the investigators will have a part-time
phlebotomist working in the field with a bilingual staff and LHW. The phlebotomist will
draw two tubes of blood from study participants at the study site. He/she will then
transport one tube of the blood in red-top tube to certified clinical labs (i.e., Johns
Hopkins Medical Institute (JHMI), Quest, LabCorp) for hepatitis B tests (e.g., HBsAg,
HBsAb (surface antibody of HBV), HBcAb (core antibody of HBV)). The other tube will be
processed for research sample banking.
3. Informing the results of screening test: All the participants will receive the results
one week after their screening. Based on the screening results, all participants will
be categorized into three groups: (1) infected (HbsAg+), (2) unprotected
(HbsAg-/HbsAb-), and (3) protected (HbsAg-/HbsAb+). The investigators will order all
screening tests and review all test results from the certified clinical labs. The
investigators will mail the results to participants who are unprotected and protected.
The investigators will not follow up healthy participants who are protected. The
investigators will be responsible for informing the results by calling those infected
individuals. The participants will provide counseling on what the results mean and
treatment options.
4. Follow up for those infected: Those infected can either be referred through their
primary care physicians to a hepatologist or directly to a hepatologist. If
participants do not have a hepatologist, participants will be referred to hepatologists
in the study team. This will be based on their language preference and geographic
location.
5. LHW Intervention/follow up for those unprotected: Those unprotected will be randomly
assigned to either the intervention or the control groups by computer-automated random
assignment. Randomization will be used to assure equivalence between groups on key
factors that may potentially influence the primary outcome of HBV vaccinations (e.g.,
gender, age, education, length of stay in the U.S.).
LHWs will conduct telephone interventions by reminding participants of a series of
vaccinations at Months 1, 2, and 6 among those assigned to the intervention group. Those who
have health insurance will be encouraged to complete vaccinations through their providers.
If participants do not have health insurance, LHWs will provide resources to help those in
the intervention access vaccinations by referring them to the AAHC, or County Health
Departments who provide vaccinations to at risk populations. Those in the control group will
receive a list of resources by mail that offers free vaccinations, such as local health
departments along with their results. Upon completing follow-up, the investigators will
provide the delayed LHW intervention for those who do not have vaccinations in the control
group.
Seven months after mailing the results, those unprotected will be followed by phone to ask
about their status of the series of vaccinations and promoters or barriers to vaccinations.
Their self-reported vaccination will be verified with medical records. Participants will be
asked to provide information about the date of vaccinations, as well as the location of the
clinic or doctor's office where participants received vaccinations. Participants will also
be asked to sign a medical release form giving project staff permission to request medical
records for their vaccinations. The bilingual interviewers are blinded about participants
being in the intervention or control group at post-test.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01182311 -
Duration of Long-term Immunity After Hepatitis B Virus Immunization
|
||
Completed |
NCT04971928 -
Phase 1 Study of GSK3228836 Pharmacokinetics in Participants With Hepatic Impairment
|
Phase 1 | |
Completed |
NCT03285620 -
A Study of AL-034 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses in Healthy Participants
|
Phase 1 | |
Completed |
NCT01884415 -
Phase III, Study to Evaluate the Efficacy of Two Different HBV Vaccination Schemes in Patients With Hepatic Cirrhosis
|
Phase 3 | |
Recruiting |
NCT05404919 -
Utilization of Hepatitis B Virus NAT+ Donors for Hepatitis B Vaccinated Lung Transplant Candidates
|
Phase 2 | |
Completed |
NCT02153320 -
Study to Evaluate the Persistence of the Cellular and Humoral Immune Response Following Vaccinations With GlaxoSmithKline (GSK) Biologicals' Candidate Vaccines Containing HBsAg and Different Adjuvants in Healthy Adult Volunteers
|
Phase 1 | |
Completed |
NCT00352963 -
Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age).
|
Phase 3 | |
Completed |
NCT03567382 -
Arresting Vertical Transmission of Hepatitis B Virus
|
Phase 4 | |
Not yet recruiting |
NCT04056728 -
A Phase IV Study to Assess the Safety of EupentaTM Inj
|
Phase 4 | |
Not yet recruiting |
NCT03604016 -
Study to Assess Efficacy of Besifovir and L-carnitine in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver
|
Phase 4 | |
Completed |
NCT00753649 -
Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants
|
Phase 4 | |
Recruiting |
NCT03027258 -
Point-of-Delivery Prenatal Test Results Through mHealth to Improve Birth Outcome
|
N/A | |
Terminated |
NCT02604199 -
A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection
|
Phase 2 | |
Completed |
NCT02540538 -
Safety and Immunogenicity of HBAI20 Hepatitis B Vaccine in Naive Adults and Non-responders
|
Phase 1 | |
Completed |
NCT02421666 -
A Comparative Trial of Improving Care for Underserved Asian Americans Infected With HBV
|
N/A | |
Completed |
NCT02169674 -
Hepatitis B Booster Study in Adolescence
|
Phase 4 | |
Completed |
NCT01917357 -
A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject
|
Phase 3 | |
Completed |
NCT01732354 -
Study for Consolidation Period of Chronic Hepatitis B
|
||
Completed |
NCT01368497 -
Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic Hepatitis B Virus (HBV) Infection
|
Phase 3 | |
Recruiting |
NCT01462981 -
Cohort of Hepatitis B Research of Amsterdam
|
N/A |